Tevogen Bio Holdings Inc (TVGN) - News Archive

In an era where technological advancements continue to reshape the landscape of healthcare, Tevogen Bio (Nasdaq: TVGN) has taken a significant leap forward by expanding its partnership with Microsoft (Nasdaq: MSFT) to l...

Tevogen Bio: Navigating Tax Obligations and Embracing AI for Future GrowthIn a press release dated October 21, 2024, Tevogen Bio (Nasdaq: TVGN), a clinical-stage biotechnology company based in Warren, New Jersey, clarif...

In an era dominated by rapid technological advancements, the intersection of biotechnology and artificial intelligence is reshaping the landscape of healthcare. Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a clinical-stage...

: Tevogen Bio Holdings Inc. a clinical-stage immunotherapy company, has garnered attention for its commitment to addressing health disparities and pioneering treatments for infectious diseases and cancers. This article...

: Tevogen Bio, a clinical-stage specialty immunotherapy company, has made significant strides in the development of off-the-shelf, genetically unmodified T-cell therapies. Recent publications highlighting promising Phas...

In an era marked by unprecedented advancements in biotechnology, Tevogen Bio Holdings Inc. (Nasdaq: TVGN) stands out as a clinical-stage specialty immunotherapy company focused on treating infectious diseases and cancer...

Tevogen Bio: Pioneering Immunotherapy in Oncology and Long COVID Amidst Mixed Financial Performance Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a clinical-stage biotechnology company, is making significant strides in the...

Tevogen Bio: Pioneering T Cell Immunotherapy to Tackle COVID-19 and Ensure Future Medical InnovationIn the ever-evolving landscape of biotechnology, Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has emerged as a key player,...

: In the evolving landscape of biotechnology, Tevogen Bio Holdings Inc. has emerged as a notable player, particularly in the advocacy for Long COVID patients. This article explores the recent engagement of Tevogen Bio l...

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment from The Patel Family, LLPWarren, N.J. - Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer, has announc...

Tevogen Bios Innovation Amplifies with Prof. Sten Vermund s Appointment as Dean of the USF Health College of Public HealthIn a groundbreaking announcement, Tevogen Bio Holdings Inc acknowledges and congratulates Profess...

In a recent statement, Tevogen Bio s founding CEO, Ryan Saadi, conveyed his unwavering belief in the company s growth strategy while firmly denying any undisclosed new issuances of dilutive securities. Saadi s remarks c...

Tevogen Bio: A Trailblazer in Immunotherapy Biotech Highlights Achievements, Growth Plans, and Share Buyback ConsiderationWARREN, N.J., July 11, 2024 - Tevogen Bio Holding Inc. (Tevogen or Tevogen Bio) (Nasdaq: TVGN), a...

Tevogen Bios R&D Leadership Discusses the Revolutionary Potential of Genetically Unmodified T Cell Technology for Treating Infectious Diseases, Cancers, and Neurological DisordersWARREN, N.J., July 10, 2024 - In a recen...

Warren, N.J., July 08, 2024 - Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (Tevogen) (Nasdaq: TVGN), extends his heartfelt congratulations to Salesforce CEO Marc Benioff on the prestigious recognition of receiving t...

Tevogen Bio Announces Positive Phase I Results for TVGN 489 in Blood Advances: A Promising Leap in COVID-19 Immunotherapy Warren, N.J., June 25, 2024 Tevogen Bio Holdings Inc. (Nasdaq: TVGN), a trailblazer in the clinic...

Tevogen Bio s Ambitious Roadmap: Revolutionizing T Cell Therapies and Strengthening Financial Stability Tevogen Bio s Bold Strategy to Shape the Future of T Cell Therapies Highlighted at Longwood Spring MIT Conference,...

Tevogen Bio Secures Up to $50 Million in Funding to Propel Research and Development InitiativesIn a major move to accelerate its research and development efforts, Tevogen Bio has entered into an agreement for up to $50...

Tevogen Bio, a leading pharmaceutical company, recently organized its inaugural post-public listing social engagement event to express gratitude to patients, first responders, elected officials, and members of the Unite...

In a significant development for the biotechnology sector, Tevogen Bio, a pioneering research and development firm, has successfully secured up to $50 million in financing. This substantial boost will not only propel th...